Print This Page

February 21, 2014

The Netherlands

Framelco—Using Monoglycerides to Fight AHPNS/EMS

Framelco, a company that develops products to replace antibiotics on farms, has developed a formulation of 1-monoglycerides to attack AHPNS/EMS.  Several lab and field trials (in vivo and in vitro) have shown that its 1-monoglycerides products have bactericidal activity against Vibrio parahaemolyticus.  This study was conducted to study the effect of 1-monoglycerides on survival of shrimp challenged with a virulent strain of Vibrio parahaemolyticus.


From Abstract: The University of Arizona (UAZ) fed juvenile Penaeus vannamei one of four treatment diets containing proprietary products supplied by Framelco for ten days prior to oral exposure to the virulent strain of Vibrio parahaemolyticus (the agent that causes acute hepatopancreatic necrosis disease, AHPNS/EMS) to determine if the products would have an effect on survival.  Survival at termination of the study in the group fed the dry 1-monoglycerides formulation was 3%; survival in the group fed the liquid 1-monoglycerides formulation (“Fra® Shrimp Protect Liquid”) was 93%.  Survival in the positive control group was 13% and survival in the negative control group was 100%.


From the Body of the Study: The animals utilized in this study were provided by UAZ and were originally obtained from Shrimp Improvement Systems.  A total of 180 SPF (specific pathogen free) P. vannamei were transferred from UAZ’s West Campus SPF facility and stocked into twelve 90-liter aquaria at 15 animals per tank.  Eight tanks were fed diets formulated with the Framelco products (two tanks for each product).  Two tanks were designated as positive controls and two tanks served as negative environmental controls.  The positive control tanks were fed a control diet that did not contain the Framelco products and challenged with Vibrio parahaemolyticus as a comparison for survival.  The negative control tanks were also fed the control diet, but were not challenged with Vibrio parahaemolyticus.  All tanks were fed their respective diets at 5% bodyweight once a day for the duration of the study.  All aquaria were outfitted with an oyster shell filter, aeration and were covered with plastic to reduce the risk of cross contamination and the negative controls were kept isolated in a separate building and fed before the Vibrio parahaemolyticus challenge tanks.  In total, four different treatments were studied; this report only focuses on two of the treatments.


Compared to the positive control group, the liquid 1-monoglyceride formulation reduced mortality by 80%.  Since the dry formulation did not show any mortality reduction, it is suggested that 1-monoglycerides need to be mixed into the feed mash in liquid form before feed pelleting to enhance the bioavailability inside the shrimp. It is thought that passage through the shrimp’s gut is too fast for dry monoglycerides to be released in the intestines.  Further study is needed to investigate the potential of this liquid formulation in the field.


Information: Devi Hermsen, R&D Manager Aquaculture, Framelco, Ruisvoorn 5, 4941 SB Raamsdonksveer, The Netherlands (phone +31-0-88- 0443300, email, webpage


Sources: 1. Emails to Shrimp News International from Framelco.  Subject: 1-Monoglycerides and Shrimp.  Devi Hermsen.  February 19 and 20, 2014.  2. Framelco.  Fra® Shrimp Protect Liquid Against EMS/AHPNS in Shrimp (P. vannamei).  University of Arizona (USA), October 2013.  Framelco Reference Code: AL_Fra_130001.  Received February 19, 2014.

Print This Page